Claudin 1 promotes migration and increases sensitivity to tamoxifen and anticancer drugs in luminal-like human breast cancer cells MCF7.
Downregulation of claudin 1, a critical tight junction protein, has been correlated with increased invasiveness in breast cancer. However, recent studies suggest that claudin 1 contributes to the progression of some molecular subtypes of breast cancer. In this study, claudin 1 promotes migration in luminal-like MCF7 human breast cancer cells and increases their sensitivity to tamoxifen, etoposide, and cisplatin. We also observed an inverse relationship between upregulation of claudin 1 and TGFβ. Collectively, our results suggest that claudin 1 has the potential to be used as a predictive marker for treatment efficacy for specific breast cancer patient subgroups.
a 1 Faculty of Health Sciences, Department of Pathology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Bowen
B
Zhou
a 1 Faculty of Health Sciences, Department of Pathology, College of Medicine , University of Manitoba , Winnipeg, Canada.|b 2 Faculty of Health Sciences, Department of Physiology and Pathophysiology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Anne
A
Blanchard
b 2 Faculty of Health Sciences, Department of Physiology and Pathophysiology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Nan
N
Wang
a 1 Faculty of Health Sciences, Department of Pathology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Xiuli
X
Ma
a 1 Faculty of Health Sciences, Department of Pathology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Jihyun
J
Han
a 1 Faculty of Health Sciences, Department of Pathology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Ingo
I
Schroedter
c 3 Faculty of Health Sciences, Department of Biochemistry and Human Genetics, College of Medicine , University of Manitoba , Winnipeg, Canada.
Etienne
E
Leygue
a 1 Faculty of Health Sciences, Department of Pathology, College of Medicine , University of Manitoba , Winnipeg, Canada.|b 2 Faculty of Health Sciences, Department of Physiology and Pathophysiology, College of Medicine , University of Manitoba , Winnipeg, Canada.
Yvonne
Y
Myal
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects* / Q000235:genetics*; D002945:Cisplatin / Q000494:pharmacology; D062445:Claudin-1 / Q000235:genetics*; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D005047:Etoposide / Q000494:pharmacology; D005260:Female; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D006801:Humans; D061986:MCF-7 Cells; D013629:Tamoxifen / Q000494:pharmacology*; D019108:Tight Junctions / Q000187:drug effects / Q000235:genetics; D016212:Transforming Growth Factor beta / Q000235:genetics
D000970:Antineoplastic Agents; D062445:Claudin-1; D016212:Transforming Growth Factor beta; D013629:Tamoxifen; D005047:Etoposide; D002945:Cisplatin
Breast cancer; Claudin 1; Estrogen; MCF7; Migration; TGFβ; Tamoxifen